KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Other Non-Current Liabilities: 2020-2025

Historic Other Non-Current Liabilities for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $1.4 million.

  • AbCellera Biologics' Other Non-Current Liabilities fell 68.79% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 68.79%. This contributed to the annual value of $1.5 million for FY2024, which is 75.13% down from last year.
  • Latest data reveals that AbCellera Biologics reported Other Non-Current Liabilities of $1.4 million as of Q3 2025, which was down 11.15% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Other Non-Current Liabilities peaked at $44.9 million during Q3 2021, and registered a low of $1.4 million during Q3 2025.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $5.3 million (2023), whereas its average is $5.0 million.
  • In the last 5 years, AbCellera Biologics' Other Non-Current Liabilities surged by 292.28% in 2021 and then plummeted by 79.10% in 2023.
  • Over the past 5 years, AbCellera Biologics' Other Non-Current Liabilities (Quarterly) stood at $35.9 million in 2021, then tumbled by 55.26% to $16.1 million in 2022, then plummeted by 63.21% to $5.9 million in 2023, then tumbled by 75.13% to $1.5 million in 2024, then slumped by 68.79% to $1.4 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.4 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.6 million for Q1 2025.